COMP <GO>
BIIB vs UNH // EV/EBITDA & P/E VALUATION
Biogen Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: BIIB 5
— UNH 9
▲ EV/EBITDA & P/E VALUATION LEADER: UNH
LAST: $253.62 (+1.59%) • MKT CAP: $36.90B
valuation
22.3x
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIIB VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIIB | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.70% | 88.57% | -12.87 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.40% | 11.47% | -5.07 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 22.3x | 16.4x | +5.85 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 5.56% | 6.48% | -0.92 | UNH | /fcf-yield <GO> |
| Operating Margin | 15.90% | 4.82% | +11.08 | BIIB | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 3.14% | +9.96 | BIIB | /net-margins <GO> |
| Revenue Growth (YoY) | 2.20% | 6.46% | -4.26 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.70 | 3.12 | +0.58 | BIIB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.74% | +0.46 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.7 | 56.0 | +10.60 | BIIB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.33 | +0.77 | BIIB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.5x | 17.1x | +9.41 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $36.90B | $364.66B | -$327.76B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIIB REV | UNH REV | BIIB GROSS % | UNH GROSS % | BIIB FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.89B | $447.57B | 75.7% | 88.7% | $2.05B | $16.07B |
| FY 2024 | $9.68B | $400.28B | 76.1% | 88.3% | $2.72B | $20.70B |
| FY 2023 | $9.84B | $371.62B | 44.0% | 89.6% | $1.10B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIIB // BETA 1.10
UNH // BETA 0.33